Abstract:The increasing knowledge of molecular drivers of tumorigenesis has fueled targeted cancer therapies based on specific inhibitors. Beyond “classic” oncogene inhibitors, epigenetic therapy is an emerging field. Epigenetic alterations can occur at any time during cancer progression, altering the structure of the chromatin, the accessibility for transcription factors and thus the transcription of genes. They rely on post-translational histone modifications, particularly the acetylation of histone lysine residues, and are determined by the inverse action of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Importantly, HDACs are often aberrantly overexpressed, predominantly leading to the transcriptional repression of tumor suppressor genes. Thus, histone deacetylase inhibitors (HDACis) are powerful drugs, with some already approved for certain hematological cancers. Albeit HDACis show activity in solid tumors as well, further refinement and the development of novel drugs are needed. This review describes the capability of HDACis to influence various pathways and, based on this knowledge, gives a comprehensive overview of various preclinical and clinical studies on solid tumors. A particular focus is placed on strategies for achieving higher efficacy by combination therapies, including phosphoinositide 3-kinase (PI3K)-EGFR inhibitors and hormone- or immunotherapy. This also includes new bifunctional inhibitors as well as novel approaches for HDAC degradation via PROteolysis-TArgeting Chimeras (PROTACs).

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylase Inhibitors as Anticancer Drugs

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

New Development of HDAC Inhibitors As Anti-Cancer Agents

Histone deacetylases and cancer: causes and therapies

Targeting histone deacetylases for cancer therapy: Trends and challenges

An Overview of HDAC Inhibitors and Their Synthetic Routes.

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Hydroxamic Acid Hybrids: Histone Deacetylase Inhibitors with Anticancer Therapeutic Potency

HDAC-targeting epigenetic modulators for cancer immunotherapy

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.